S32826 disodium

• CAT Number: I010760
• CAS Number: 1103672-43-0
• Molecular Formula: C21H34NNa2O4P
• Molecular Weight: 441.45
• Purity: ≥95%
• Synonyms: disodium;N-[4-(phosphonatomethyl)phenyl]tetradecanamide
• InChI: InChI=1S/C21H36NO4P.2Na/c1-2-3-4-5-6-7-8-9-10-11-12-13-21(23)22-20-16-14-19(15-17-20)18-27(24,25)26;;/h14-17H,2-13,18H2,1H3,(H,22,23)(H2,24,25,26);;/q;2*+1/p-2
• InChIKey: DGRFALMFDGBLCP-UHFFFAOYSA-L
• SMILES: CCCCCCCCCCCCCC(=O)NC1=CC=C(C=C1)CP(=O)([O-])[O-].[Na+].[Na+]

S32826 disodium is a potent autotaxin inhibitor, with an IC50 of 8.8 nM. S32826 disodium shows similar inhibitory effects at various autotaxin isoforms (α, β and γ). S32826 disodium inhibits LPA release from adipocytes[1].
S32826 (0.001-10 μM; 10 days) disodium dose-dependently inhibits the release of lyso-phosphatidic acid (LPA) by 3T3-F442A adipocytes with an IC50 of 90 nM and a maximal inhibition of 80% at 500 nM[1].
S32826 (1 μM; 24 h) disodium inhibits Dexamethasone-induced increases in autotaxin (ATX) mRNA expression in HTM cells and lysoPLD activity in conditioned media. S32826 disodium inhibits Dexamethasone-induced the phosphorylation of MLC and cofilin, mRNA upregulation of COL1A1 and COL4A1, and expression of α-SMA, fibronectin and collagen-1 in the HTM cells[2].
Topical application of S32826 (2-10 mM; 2 h-5 d) disodium decreases intraocular pressure (IOP) in a dose- and time-dependent manner in rabbits[2].
S32826 (∼2 µM; single intracameral injection) disodium reduces the IOP in rabbits, with the ocular hypotensive response lasting for more than 48 hrs[2].
S32826 (10 mg/kg; p.o., i.p., s.c., and i.v.) disodium shows poor in vivo stability and/or bioavailability[1].

Reference

[1]. Ferry G, et, al. S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool. J Pharmacol Exp Ther. 2008 Dec;327(3):809-19.
 [Content Brief]

[2]. Honjo M, et, al. Role of the Autotaxin-LPA Pathway in Dexamethasone-Induced Fibrotic Responses and Extracellular Matrix Production in Human Trabecular Meshwork Cells. Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):21-30.
 [Content Brief]

[3]. Iyer P, et, al. Autotaxin-lysophosphatidic acid axis is a novel molecular target for lowering intraocular pressure. PLoS One. 2012;7(8):e42627.
 [Content Brief]